Neovascular age-related macular degeneration (wet AMD) is the leading cause of blindness among older people in the United States. Until mid-2006, treatments for this disease had been known for their ability to reduce the rate of disease progression. Since then, a new therapeutic option that has been shown to maintain visual acuity has been made available. This publication reviews the history of, and recent advances in, the treatment of wet AMD.
Overview of Age-Related Macular Degeneration
Treatments for Age-Related Macular Degeneration
Panel Discussion: Ranibizumab Therapy in the Managed Care Market